Cerebellar Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials
The rate of LID development is from 3 to 94%
Abstract
In a previous study with optimal use of Levodopa, the prevalence of LID could be
Levodopa-induced dyskinesia affected 30% of the patients with PD in our cohort
Levodopa has a superior antiparkinsonian effect than dopamine agonists making it the standard of care for patients with Parkinson's disease (PD)
Levodopa-induced dyskinesias (LID) belong to the most common dose-limiting adverse effects of levodopa therapy
Areas covered: In this review, the authors discuss the treatment of LID
Introduction: Levodopa-induced dyskinesia frequently complicates long-term Parkinson's disease
Thus LID can occur at the peak effect of levodopa (mainly chorea) or when the levels are lower or in-between doses (usually dystonia)
Dyskinesia is a common motor complication associated with the use of levodopa to treat Parkinson’s disease
Levodopa-induced dyskinesias (LID) are abnormal involuntary movements that develop progressively with repeated dopamine replacement therapy in Parkinson's disease (PD)
Most patients develop LID within 10 years of PD onset and the cause has been attributed to
Parkinson’s disease therapy is still focused on the use of L-3,4-dihydroxyphenylalanine (levodopa or L-dopa) for the symptomatic treatment of the main clinical features of the disease, despite intensive pharmacological research in the last few decades
1002/ana
Dyskinetic disorders are characterized by excess of motor activity that may interfere with normal movement control
LID is associated with Parkinson's disease (PD), emerging as a consequence of chronic the
2 Severe LID significantly affects quality of life and is an important contributor to weight loss